What is HC Wainwright’s Estimate for ALDX FY2029 Earnings?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Research analysts at HC Wainwright lowered their FY2029 EPS estimates for shares of Aldeyra Therapeutics in a report released on Monday, May 11th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will post earnings of $0.15 per share for the year, down from their previous forecast of $0.24. HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.44) per share.

Several other equities research analysts have also weighed in on the company. Wall Street Zen lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.50.

Aldeyra Therapeutics Stock Performance

NASDAQ ALDX opened at $1.76 on Tuesday. Aldeyra Therapeutics has a 1 year low of $1.07 and a 1 year high of $6.18. The business’s fifty day moving average is $2.47 and its two-hundred day moving average is $4.12. The stock has a market capitalization of $106.16 million, a P/E ratio of -3.09 and a beta of 1.16.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07.

Insiders Place Their Bets

In other Aldeyra Therapeutics news, Director Richard Douglas bought 70,000 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were bought at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the acquisition, the director directly owned 195,000 shares of the company’s stock, valued at approximately $273,000. This trade represents a 56.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALDX. Krilogy Financial LLC purchased a new stake in Aldeyra Therapeutics in the 1st quarter worth approximately $26,000. Abel Hall LLC purchased a new position in shares of Aldeyra Therapeutics during the 1st quarter valued at $26,000. Chicago Partners Investment Group LLC acquired a new position in shares of Aldeyra Therapeutics in the first quarter worth $33,000. Caption Management LLC increased its stake in shares of Aldeyra Therapeutics by 110.6% in the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 132,358 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC purchased a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth $52,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.